120 related articles for article (PubMed ID: 28696419)
1. Associations between the C677T and A1298C polymorphisms of MTHFR and the toxicity of methotrexate in childhood malignancies: a meta-analysis.
Zhu C; Liu YW; Wang SZ; Li XL; Nie XL; Yu XT; Zhao LB; Wang XL
Pharmacogenomics J; 2018 May; 18(3):450-459. PubMed ID: 28696419
[TBL] [Abstract][Full Text] [Related]
2. Association of methylenetetrahydrofolate reductase (
Yang R; Pu D; Tan R; Wu J
Arch Endocrinol Metab; 2022 Sept 08; 66(4):551-581. PubMed ID: 35758831
[TBL] [Abstract][Full Text] [Related]
3. Correlation between gene polymorphism and adverse reactions of high-dose methotrexate in osteosarcoma patients: a systematic review and meta-analysis.
Liu B; Liu G; Liu B; Guo Y; Peng N; Li T
World J Surg Oncol; 2024 Jan; 22(1):19. PubMed ID: 38212758
[TBL] [Abstract][Full Text] [Related]
4. Involvement of the
Guo Q; Sun JL; Li R; Li X
Int J Gen Med; 2024; 17():1221-1231. PubMed ID: 38559593
[TBL] [Abstract][Full Text] [Related]
5.
Samii A; Aslani S; Imani D; Razi B; Samaneh Tabaee S; Jamialahmadi T; Sahebkar A
Int J Cardiol Heart Vasc; 2023 Dec; 49():101293. PubMed ID: 38035258
[TBL] [Abstract][Full Text] [Related]
6. Severe Adverse Toxic Effects of Low-Dose Methotrexate Treatment on an Ectopic Pregnancy Patient With Methylenetetrahydrofolate Reductase Mutations: A Case Report.
Yu H; Wang W; Liang H; Wang K; Ling B
Front Med (Lausanne); 2021; 8():738315. PubMed ID: 34869432
[No Abstract] [Full Text] [Related]
7. GENETIC PREDICTORS OF TOXIC EFFECTS OF METHOTREXATE IN CANCER PATIENTS.
Fishchuk L; Skavinska O; Ievseienkova O; Rossokha Z; Sheiko L
Exp Oncol; 2024 Feb; 45(4):399-408. PubMed ID: 38328850
[TBL] [Abstract][Full Text] [Related]
8. MTRR A66G, RFC1 G80A, and MTHFR C677T and A1298C Polymorphisms and Disease Activity in Mexicans with Rheumatoid Arthritis Treated with Methotrexate.
González-Mercado MG; Rivas F; Gallegos-Arreola MP; Morán-Moguel MC; Salazar-Páramo M; González-López L; Gámez-Nava JI; Muñoz-Valle JF; Medina-Coss Y León R; González-Mercado A; Aceves MA; Dávalos NO; Macías-Chumacera A; Dávalos IP
Genet Test Mol Biomarkers; 2017 Nov; 21(11):698-704. PubMed ID: 28994615
[TBL] [Abstract][Full Text] [Related]
9. A cost-effectiveness analysis of maternal CYP2D6 genetic testing to guide treatment for postpartum pain and avert infant adverse events.
Moretti ME; Lato DF; Berger H; Koren G; Ito S; Ungar WJ
Pharmacogenomics J; 2018 May; 18(3):391-397. PubMed ID: 28696420
[TBL] [Abstract][Full Text] [Related]
10. Associations between gene polymorphisms and treatment outcomes of methotrexate in patients with juvenile idiopathic arthritis.
Chen Y; Zou K; Sun J; Yang Y; Liu G
Pharmacogenomics; 2018 Apr; 19(6):529-538. PubMed ID: 29589488
[TBL] [Abstract][Full Text] [Related]
11. The influence of MTHFR genetic polymorphisms on adverse reactions after methotrexate in patients with hematological malignancies: a meta-analysis.
Yao P; He X; Zhang R; Tong R; Xiao H
Hematology; 2019 Dec; 24(1):10-19. PubMed ID: 30024839
[TBL] [Abstract][Full Text] [Related]
12. Folate pathway genetic polymorphisms modulate methotrexate-induced toxicity in childhood acute lymphoblastic leukemia.
Yousef AM; Farhad R; Alshamaseen D; Alsheikh A; Zawiah M; Kadi T
Cancer Chemother Pharmacol; 2019 Apr; 83(4):755-762. PubMed ID: 30684021
[TBL] [Abstract][Full Text] [Related]
13. Involvement of C677T MTHFR variant but not A1298C in methotrexate-induced toxicity in acute lymphoblastic leukemia.
Frikha R; Jemaa MB; Frikha F; Turki I; Elloumi M; Keskes L; Kamoun H; Rebai T
J Oncol Pharm Pract; 2021 Sep; 27(6):1382-1387. PubMed ID: 32865163
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
15. Pharmacogenetic Variants in MTHFR Gene are Significant Predictors of Methotrexate Toxicities in Bangladeshi Patients With Acute Lymphoblastic Leukemia.
Zahra FT; Nahid NA; Islam MR; Al-Mamun MMA; Apu MNH; Nahar Z; Kabir AL; Biswas SK; Ahmed MU; Islam MS; Hasnat A
Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):e58-e65. PubMed ID: 31884153
[TBL] [Abstract][Full Text] [Related]
16. Genetic markers in methotrexate treatments.
Giletti A; Esperon P
Pharmacogenomics J; 2018 Dec; 18(6):689-703. PubMed ID: 30237581
[TBL] [Abstract][Full Text] [Related]
17. Use of MTHFR C677T polymorphism and plasma pharmacokinetics to predict methotrexate toxicity in patients with acute lymphoblastic leukemia.
Mahmoud LB; Mdhaffar M; Frikha R; Ghozzi H; Hakim A; Sahnoun Z; Elloumi M; Zeghal K
Adv Clin Exp Med; 2018 Aug; 27(8):1061-1068. PubMed ID: 29911750
[TBL] [Abstract][Full Text] [Related]
18. A common mutation in the methylenetetrahydrofolate reductase gene is associated with an accumulation of formylated tetrahydrofolates in red blood cells.
Bagley PJ; Selhub J
Proc Natl Acad Sci U S A; 1998 Oct; 95(22):13217-20. PubMed ID: 9789068
[TBL] [Abstract][Full Text] [Related]
19. Polymorphisms within methotrexate pathway genes: Relationship between plasma methotrexate levels, toxicity experienced and outcome in pediatric acute lymphoblastic leukemia.
Esmaili MA; Kazemi A; Faranoush M; Mellstedt H; Zaker F; Safa M; Mehrvar N; Rezvany MR
Iran J Basic Med Sci; 2020 Jun; 23(6):800-809. PubMed ID: 32695297
[TBL] [Abstract][Full Text] [Related]
20. Polymorphisms of SLC19A1 80 G>A, MTHFR 677 C>T, and Tandem TS Repeats Influence Pharmacokinetics, Acute Liver Toxicity, and Vomiting in Children With Acute Lymphoblastic Leukemia Treated With High Doses of Methotrexate.
Cwiklinska M; Czogala M; Kwiecinska K; Madetko-Talowska A; Szafarz M; Pawinska K; Wieczorek A; Klekawka T; Rej M; Stepien K; Halubiec P; Lazarczyk A; Miklusiak K; Bik-Multanowski M; Balwierz W; Skoczen S
Front Pediatr; 2020; 8():307. PubMed ID: 32612964
[No Abstract] [Full Text] [Related]
[Next] [New Search]
